Vector Centre Advances mRNA Vaccine Pipeline for HIV, Monkeypox, and Tick-Borne Encephalitis
核心洞察
The Vector State Research Centre (搜索) in Novosibirsk is simultaneously developing three mRNA vaccine candidates targeting HIV (搜索), monkeypox (搜索), and tick-borne encephalitis (搜索), currently in animal immunogenicity testing.
Senior researcher Larisa Karpenko announced the developments at the Engineering Biology and Biopharmaceuticals conference, alongside earlier mRNA vaccines for COVID-19 (搜索), H1N1 influenza, and H5Nx avian influenza.
Vector is also pursuing mRNA-based therapies for diseases linked to defective protein synthesis, including anaemia (搜索), and collaborating on personalized neoantigen cancer vaccines.
The Vector State Research Centre (搜索) of Virology and Biotechnology in Novosibirsk is advancing a broad pipeline of mRNA-based vaccine candidates, with three new programs targeting HIV (搜索), monkeypox (搜索), and tick-borne encephalitis (搜索) now undergoing immunogenicity testing in laboratory animals. Senior researcher Larisa Karpenko disclosed the developments during a presentation at the Engineering Biology and Biopharmaceuticals conference held in Novosibirsk.
The three candidates represent an expansion of Vector's growing mRNA platform, which has already produced experimental vaccines against COVID-19 (搜索), seasonal influenza A(H1N1) (搜索), and highly pathogenic avian influenza H5Nx (搜索). According to Karpenko, these earlier candidates have demonstrated the ability to induce specific immune responses and confer protection in laboratory animals subjected to viral challenge.
mRNA Platform Technology
The mRNA vaccine approach employed by Vector relies on delivering genetic instructions that encode a protein characteristic of the target pathogen. A lipid shell encapsulates the RNA, protecting it from enzymatic degradation and facilitating cellular entry. Once inside cells, the mRNA directs the production of the pathogen-derived protein, prompting the immune system to mount a targeted response.
Beyond Infectious Diseases
Vector's research portfolio extends beyond prophylactic vaccines for infectious diseases. The centre is actively developing therapeutic interventions for inherited and acquired conditions stemming from defective protein synthesis in cells, including anaemia (搜索). In a parallel effort, Vector scientists are collaborating with researchers from the Tomsk National Research Medical Centre (搜索) on personalized cancer vaccines built around neoantigens—tumor-specific protein fragments that can be leveraged to train the immune system to recognize and attack malignant cells.
Oncolytic Virus Program Shows Early Clinical Signal
In a related development, the Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences, working jointly with the Vector centre and the company Oncostar, has advanced an oncolytic virus-based drug for breast cancer (搜索) through a Phase I clinical trial. The study enrolled patients with advanced-stage disease. Results indicated that approximately 55% of participants experienced either tumor shrinkage or disease stabilization, providing an early signal of clinical activity that may support further investigation.
The breadth of Vector's mRNA and oncolytic virus programs underscores the centre's ambition to establish a diversified biopharmaceutical pipeline spanning infectious disease prevention, cancer immunotherapy, and treatments for protein-synthesis disorders.